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Group-2 innate lymphoid cells (ILC2) play critical roles in the initiation and maintenance
of type-2 immune responses, predominantly through their production of the type-2
cytokines IL-5, IL-9, and IL-13. ILC2 are essential for the efficient elimination of
helminth parasites, but also contribute to the detrimental type-2 immune responses
that underlie diseases such as asthma and allergy. While several transcription factors
have been identified that regulate the development and function of ILC2, less is known
about the post-transcriptional mechanisms that regulate these processes. We identified
micro-RNAs (miRNAs) that are co-ordinately regulated in ILC2 from mice exposed to two
different stimuli, namely IL-33 “alarmin” administration or Nippostrongylus brasiliensis
parasitic worm infection. miR-155 is upregulated in ILC2 in response to both stimuli
and miR-155−/− mice had impaired IL-33-driven ILC2 responses. Using mixed bone
marrow chimeras, we demonstrate that this deficit is intrinsic to ILC2 and that miR-155
protects ILC2 from apoptosis, while having little impact on ILC2 proliferation or cytokine
production. These data reveal a subset of miRNAs that are regulated upon ILC2 activation
and establish a specific role for miR-155 in regulating ILC2 survival following activation.
Keywords: miR-155, ILC2, apoptosis, IL-33, type-2 immunity
INTRODUCTION
Group-2 innate lymphoid cells (ILC2) are tissue-resident immune cells that represent a significant
early source of the type-2 cytokines IL-5, IL-9, and IL-13 and play important roles in the initiation
and maintenance of type-2 immune responses. ILC2 play critical roles in the elimination of
helminth parasites (1), but also in the etiology of allergic diseases such as eczema (2) and asthma
(3–5). ILC2 are activated by damage-associated signals, such as the epithelium-derived cytokines
IL-25, IL-33 (6), and TSLP (7), which bind to the receptors IL-17RB, ST2 (IL-1RL1), and TSLP-R,
respectively, on the ILC2 surface. In addition, ILC2 are activated by arachidonic acid metabolites
such as PGD2, LTD4, and PGD4 (8), but inhibited by lipoxin A4 (9) and IFNγ (10).
ILC2 originate from common lymphoid progenitors (CLP) and several key transcription factors
have been identified that regulate their development and function (11). Development of all ILCs
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requires the combined actions of several key factors, including
Id2, Gata3, PLZF, and TCF-1 (12). Lineage-specific factors, such
as RORα, Bcl11b, and high levels of Gata3, are subsequently
required to specify the ILC2 lineage specifically.
Although there has been significant focus on the transcription
factors that regulate ILC2 function, relatively little is known
about the post-transcriptional mechanisms that govern ILC2
development and function. MicroRNAs (miRNAs) are important
regulators of cell fate decisions and act to co-ordinately repress
the expression of multiple genes in order to drive cellular re-
programming. Indeed, miRNAs have been shown to play critical
roles in Th2 cell development and function and perturbations in
the expression of particular miRNAs are associated with allergy
and asthma (13, 14). For example, miR-24 and miR-27 cooperate
to suppress Th2 cell differentiation, serving to repress expression
of the canonical Th2 transcription factor GATA3, as well as other
critical Th2 cell regulators such as Ikzf1, and IL-4 in mice (15).
Conversely, miRNA (miR)-19a promotes Th2 cell development
through its repression of negative regulators of TCR signaling
(Pten) and type-2 cytokine production (Socs1 and Tnfaip3) and
is reported to be upregulated in T cells from asthmatic airways
(16). Recently, the miR-17∼92 cluster that includes miR-19a was
also found to promote IL-5 and IL-13 production from ILC2 (17).
A Th2 cell-intrinsic role has also been identified for miR-155,
which is contained within exon 2 of the non-coding RNA, B cell
integration cluster (bic). Inhibitors of miR-155 reduced IL-13 and
IL-5 expression by Th2 cells, suggesting that miR-155 contributes
to Th2 effector function, and miR-155-deficient mice exhibited
significantly reduced airway inflammation and eosinophilia in
response to house dust mite challenge or a model of ovalbumin-
induced allergic airway inflammation (18, 19). A number of
putative miR-155 targets have been identified in Th2 cells
including genes encoding the sphingosine-1-phospate receptor
1 (S1PR1) (19), which may control lymphocyte egress from
lymphoid tissue, the transcription factor PU.1 (18), a negative
regulator of type-2 cytokine production, andmetabolic regulators
such as the mTOR binding partner, RICTOR (19). Recently,
miR-155 has also been reported to regulate ILC2 and it was
observed that miR-155-deficient mice have reduced numbers of
ILC2 in response to ovalbumin-induced lung inflammation (20).
Furthermore, ILC2 from miR-155−/− mice exhibited impaired
proliferation and IL-13 production in response to IL-33, though
this study did not fully address whether this reflected an ILC2-
intrinsic role for miR-155, or an effect of miR-155-dependent
stromal or T cell-dependent factors (20). Indeed, allergen-
induced IL-33 induction in the lung was significantly impaired
in miR-155−/− animals, suggesting pleiotropic roles for this
miRNA (20).
To identify miRNAs that regulate ILC2 development and
function, we performed comprehensive microarray analysis,
with PCR verification, to identify miRNA expression in resting
ILC2 from naïve mice, and activated ILC2 isolated from mice
administered exogenous IL-33, or infected with the parasitic
helminth Nippostrongylus brasiliensis. A subset of miRNAs
was differentially expressed in both IL-33 and N. brasiliensis
stimulated ILC2, while other miRNAs were regulated according
to the particular stimulus used. Among those co-ordinately
regulated by both IL-33 and N. brasiliensis infection were
immunoregulatory miRNAs, including miR-155. Focussing on
miR-155, due to its reported roles in type-2 immunity,
we used mixed bone marrow (BM) chimeras and in vitro
proliferation and survival assays to demonstrate that ILC2-
intrinsic expression of miR-155 is required to protect ILC2 from
apoptosis.
MATERIALS AND METHODS
Mice
bic/miR155-deficient mice (Mir155tm1.1Brd) (21) and Rorafl/fl x
Il7raCre mice have been described previously (1) and CD45.1+
transgenic (B6SJL) mice were produced in-house. All mouse
experiments were undertaken with the approval of the UKHome
Office. Mice were kept at a specific pathogen-free facility.
Murine Models
Three murine models were used to study ILC2 responses in the
presence or absence of miR-155. For IL-33 exposures mice were
injected intraperitoneally with 1 µg of recombinant mouse IL-
33 in PBS for 3 consecutive days. For IL-2/IL-25 expansion of
ILC2 in vivo, mice were injected with 0.5 µg IL-2, 2.5 µg anti-
IL2 and 0.5 µg of IL-25 in PBS for 3 consecutive days (1). Mice
were euthanized on day 4. For N. brasiliensis infection, mice
were administered 500 viable third-stage N. brasiliensis larvae
subcutaneously and culled on day 5. Infection was confirmed by
enumerating adult worm burden in the small intestine.
Cell Sorting and Flow Cytometry
In initial experiments to measure the miR response, abdominal
(mesenteric, para-aortic, and inguinal) lymph nodes were
harvested. For quantification experiments, mesenteric lymph
nodes (MLN) frommice were homogenized and cell suspensions
stained using fluorescent antibodies. For cell sorting, T-
cells were defined as CD3+CD4+ cells and ILC2 were
defined as Lin−ICOS+ cells. Lineage included CD3, 4, 5,
8, 11b, 11c, 19, B220, FceRI, NK1.1, and Ter-119. For
flow cytometry staining (BD Fortessa) ILC2 were defined as
live CD45+Lin−Sca1+ICOS+KLRG1+. For a complete list of
antibodies used please see below.
Antibodies
The following antibodies were used: FITC-conjugated anti-CD3
(Biolegend cat#100306, clone 145-2C11, RRID:AB_312671),
FITC-conjugated anti-CD4 (BD, clone H129.19, Cat# 553651,
RRID:AB_394971), FITC-conjugated anti-CD8 (eBioscience
Clone 53.6.7, Cat# 11-0089-42, RRID:AB_10718971), FITC-
conjugated anti-CD11b (Biolegend, clone M1/70 Cat# 101206,
RRID:AB_312789), FITC-Conjugated anti-CD11c (eBioscience,
clone N418, Cat# 11-0114-81, RRID:AB_464939), FITC-
conjugated anti-CD19 (eBioscience Clone ID3 Cat# 11-0193-82,
RRID:AB_657666), FITC-conjugated anti-B220 (eBioscience
clone RA3-6B2 Cat# 11-0452-82, RRID:AB_465054),
FITC-conjugated anti-FcERI (eBioscience clone MAR-1 Cat# 11-
5898-81, RRID:AB_465307), FITC-conjugated anti-NK1.1 (BD,
clone PK136 Cat# 553164, RRID:AB_394676), FITC-conjugated
anti Ter119 (eBioscience clone Ter-119 Cat# 11-5921-81,
RRID:AB_465310), APC-conjugated anti-ICOS (eBioscience
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clone C398.4A Cat# 17-9949-80, RRID:AB_11149500),
Pe-conjugated anti-KLRG1 (eBioscience clone 2F1 Cat#
12-5893-80, RRID:AB_10597431), FITC-conjugated anti-ST2
(MD Bioscience Clone DJ8 Cat# 101001F, RRID:AB_947549),
fixable viability dye R780 (eBioscience 65-065-14), BV510
conjugated anti-CD45.1 (BioLegend Clone A20 Cat# 110741,
RRID:AB_2563378), AlexaFluor700-conjugated anti-CD45.2
(eBioscience clone 104 Cat# 11-0454-81, RRID:AB_465060),
biotinylated anti-CD127 (Biolegend Clone SB/199 Cat# 135006,
RRID:AB_2126118), PE-conjugated anti-Flt3l (eBioscience
Clone A2F10 Cat# 15-1351-82, RRID:AB_494219), APC-
conjuated anti-LPAM-1 (BioLegend clone Dakt32 Cat#
120608, RRID:AB_10730607), PeCF594-conjugated anti-
CD25 (BD clone PC61), PeCy7-conjugated anti Sca-1
(eBioscience clone D7 Cat# 25-5981-82, RRID:AB_469669),
PerCP-Cy5.5-conjugated anti-ICOS (BioLegend C398.A4 Cat#
313518, RRID:AB_10641280), FITC-conjugated anti-CD117
(BD clone 2BL Cat# 553354, RRID:AB_394805), BV510-
conjugated anti-CD45 (BioLegend Clone 3F11 Cat# 103138,
RRID:AB_256306), and eFlour450 conjugated anti-CD3, 4,
11b, 11c, 19, NK1.1, FcER1, F4/80, Ter119 (all eBioscience
clones 145-2C11 Cat# 48-0031-80, RRID:AB_10733280, Gk1.1
Cat# 48-0041-82, RRID:AB_10718983, M1/70 Cat# 48-0112-82,
RRID:AB_1582236, N418 Cat# 48-0114-82, RRID:AB_1548654,
eBio103 Cat# 48-0193, RRID:AB_2043815), PK136 Cat#
48-5941-80, RRID:AB_2043878, Mar1 Cat# 48-5898-80,
RRID:AB_2574085, BM8 Cat# 48-4801-80, RRID:AB_1548756
and Ter-119 Cat# 48-5921-82, RRID:AB_1518808, respectively),
anti-IL-2 for injection (2Bscientific clone JES6-IAI2), PE-
conjugated anti-Flt3 (E-bioscience clone A2F10 Cat# 15-1351-82,
RRID:AB_494219).
cDNA Synthesis, qPCR, and Microarray
RNA was isolated using trizol and the Qiagen RNeasy kits.
Samples were analyzed using the Agilent RNA 6000 Pico Chip
and 2100 Bioanalyser. cDNA for qPCR was synthesized using the
Quantitec Reverse Transcription Kit and the Taqman microRNA
assay (mmu-miR-155 and U6) according to the manufacturers’
specifications.
MicroRNA Screen
ILC2 (CD3−CD4−Lin−ICOS+ cells) were isolated from naïve,
IL-33 or N. brasiliensis treated mice using fluorescent cell
sorting (Sony iCyt Synergy cell sorter) and stored after the
addition of TRIzol LS. RNA was extracted using chloroform
phase separation, followed by DNase treatment and further
purification using Qiagen RNeasy micro kits (performing
washes with 100% ethanol to preserve short RNA sequences).
RNA integrity was checked using a RNA6000 Pico Kit on an
Agilent 2100 Bioanalyzer. Labeling, microarray hybridization,
washing, scanning and feature extraction were performed as
described previously (22). As up to 150 mice had to be used to
extract sufficient microRNA for microarray analysis of naïve
mice, only a single measurement was taken due to cost and
ethical considerations. Microarrays were scanned on an Agilent
Microarray Scanner (G2565CA) using miRNA_107_Sep09
scanning protocol (Agilent). Spot intensities were then extracted
using Agilent’s Feature Extraction software v10.7.3. Microarray
results were compared to qPCR, obtained using Exiqon’s
miRCURY LNA Universal RT microRNA PCR Mouse&Rat
plates I and II V3.M.
Retroviral Construct Preparation
A pSiren-RetroQ retroviral construct (Clontech) was modified
by replacing the puromycin resistance gene with an mCherry-
expressing gene. Two double stranded oligonucleotides (5′-GAT
CCACCCCTATCACAATTAGCATTAATTCAAG AGATTA
AT GCTAATTGTGATAGGGGTTTTTTTG−3′, 5′-AATT
CAAAAAAAC CCCTATCACAAT TAGCATTAATCTCTT
GAATTAATGCTAATTGTGATAGGGGTG−3′, controls 5′-
GAT CCGATTATGTGAGAGCGTGTATTATTTCAAGAG
AATAATACACGCTCTCACATAATCTTTTTACGCGTG-3′,
5′-AATTCACGCGTAAAAAAGATTATGTGAGAGCGTGTAT
TATTCTCTTGAATAATACACGCTCTCACATAATCG-3′)
with homology to the entire region of mmu-miR-155-5p
and containing BamHI/EcoRI overhangs and an internal
hybridisation region, were annealed and ligated downstream of
the U6 promoter of the pSiren-retroQmCherry retroviral vector.
Construction and Collection of the
Recombinant Retrovirus
HEK-293T cells maintained in DMEM/10%FCS/penicillin
and streptomycin were co-transfected (5 × 106 cells) using
polyethylenimine with 10 µg of anti-miR-155 pSiren-retroQ
and 15–20 µg of the ecotrophic packaging vector pCL-Eco
(Imgenex) and the cells were incubated at 37◦C. After 72 h, the
supernatant containing the retroviral particles was collected
and filtered through a low protein-binding filter (0.45µm). The
supernatant was centrifuged at 25 k rpm at 4◦C for 2 h using
an ultracentrifuge and the supernatant removed. The virus
particles were resuspended in a primary cell culture compatible
media (RPMI, 10% FCS, P/S) for a 20x concentration and stored
at−80◦C.
ILC2 Transduction
MLN from IL-2/anti-IL-2/IL-25 stimulated mice were collected
and pooled. The mouse tissue cell supsension was then
depleted of lineage positive cells using biotinylated antibodies
(B220, CD3e, CD4, CD5, CD8, CD11b, CD11c, FceRIa, Gr-
1, NK 1.1, TER119) and Dynabeads (Thermo Fisher) for
magnetic separation. Lineage negative cells were cultured
for 24 h with IL-33 (10 ng/ml) and IL-7 (10 ng/ml). 2 ×
105 ILC2 were seeded per well and transduced with viral
supernatant. The cells were then centrifuged at 900 × g,
at 32◦C for 90min and incubated in the presence of IL-33
(10 ng/ml) and IL-7 (10 ng/ml). After 72 h, transduced cells (Live,
Lineage−ICOS+KLRG1+mCherry+) were sorted using an iCyt
Synergy cell sorter (Sony). Isolated ILC2 were cultured with IL-
33 (10 ng/ml) and IL-7 (10 ng/ml). Cells were counted every day
for 5 days.
Apoptosis
JC-1 staining was performed according to the manufacturers
(ABCAM) instructions. AnnexinV staining was performed using
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eBioscience PerCP-efluor710 labeled AnnexinV and a fixable
viability dye. As controls, mitochondria were depolarized using
FCCP or cell death induced using heat shock.
Statistical Analysis
Spot intensities from the Agilent Microarray were obtained with
background correction and gProcessedSignal data were analyzed.
The minimum measure of variability was calculated and added
to each value to remove negative values and data was Log2
transformed. Principal component analysis was performed as
well as a two-way ANOVA to assess miRNA fold changes and
generate hierarchical clustering heat maps. All miRNA analysis
was performed using Partek R© Genomics Suite R© software,
version 7.17 Copyright©; 2017. Other data were analyzed using
Graphpad Prism using t-tests or ANOVA, as indicated for
individual experiments.
RESULTS
Differential Regulation of miRNAs in ILC2
Following Activation
To determine the expression of miRNAs in ILC2 following
activation, we isolated ILC2 (CD3−CD4−Lineage−ICOS+) from
the abdominal lymph nodes of naïve wildtype (WT) mice or
WT mice treated with IL-33 or infected with N. brasiliensis (day
5 post-infection). miRNA expression profiles were established
using microarray and confirmatory PCR (IL-33 data only, data
not shown). Principle component analysis (PCA) is shown in
Figure 1A. Many miRNA already identified to be involved with
lymphocyte activity were detected in this data set and their
relative expression between stimulated and naive samples are
shown (Figure 1B). Data revealed 95 miRNAs in ILC2 that
were differentially regulated in response to both IL-33 and
N. brasiliensis, with a further 67 unique to IL-33 and 21 unique
to N. brasiliensis (Figure 1C, Supplementary Tables 1–7). Of
these, miR-155 was selected for further study as it ranked highly
in fold-change (18.9-fold increase) in IL-33-treated mice and
has been implicated previously in lymphocyte development and
Th2 cell immunity. miRNA differentially expressed between
naïve ILC2 and ILC2 following in vivo IL33-stimulation or
N. brasiliensis-infection, and T cells upon N. brasiliensis-
infection indicated considerable co-incidence of miRNA
modulation (Figure 1C and Supplementary Tables 1–7).
Notably 34 miRNA were found to be changed in all stimulated
populations (Figure 1C). These 34 miRNAs included mir-
155, mir-146a, and mir-19a (Figure 1C), of which mir-155
was among the most highly expressed in activated cells;
intensity data for miR155 are shown for each sample
(Figure 1D).
miR-155 Is Required for ILC2 Expansion
Response to IL-25 or IL-33
To study the effect of miR-155 on ILC2 we injected both wildtype
(WT) and miR155−/− mice with IL-33 to expand ILC2 in vivo.
ILC2 were isolated from the mesenteric lymph nodes (MLN) and
enumerated. As expected, IL-33 increased ILC2 numbers in WT
mice. However, there were significantly fewer ILC2 in theMLN of
miR-155-deficient mice treated with IL-33 (Figures 2A,B). There
were no differences in the expression of ST2 (the IL-33 receptor)
between WT and miR155−/− ILC2 (Figure 2C). Furthermore,
although administration of IL-25 in combination with a complex
of IL-2 and anti-IL2 (to maintain the slow release of IL-2 and
maximize ILC2 proliferation) also induced an expansion in ILC2
numbers inWTmice, this increase was reduced in the absence of
miR-155 (Figure 2D). Thus, miR-155 is required for the increase
in ILC2 numbers in response to IL-25 or IL-33 stimulation.
Haematopoetic Cell miR-155 Is Critical for
ILC2 Expansion in Response to IL-33
Early studies suggested that miR-155 is only expressed in
haematopoetic cells (23). However, subsequent studies have
reported expression of miR-155 in other cell types, such as
endothelial cells (24, 25), epithelial cells (26, 27) and fibroblasts
(28). To exclude potential miR-155-related perturbation of
epithelium-derived cytokines or other stromal cell factors, we
generated bone marrow (BM) chimeric mice to study the
effects of miR-155 within the haematopoietic compartment.
Lethally irradiatedWT CD45.1+ (B6SJL) mice received CD45.2+
BM from WT mice, miR-155-deficient mice, or an equal
mix of WT and miR155−/− BM cells. Following a period
of 3 months (to allow reconstitution of donor-derived ILC2
populations), mice were treated with intra-peritoneal IL-33 and
the number of donor-derived ILC2 enumerated. In mice that
had received miR155−/− BM only, there were fewer ILC2
in the MLN compared to mice that had received WT BM
(Figure 3A). There were no differences between WT and mixed
WT/miR155−/− BM transplanted mice, indicating that the
absence of miR-155 does not have a trans-inhibitory effect.
Thus, the deficit in ILC2 numbers in miR-155-deficient mice
is dependent on haematopoietic lineages, but not stromal cell
signals.
miR-155 Does Not Regulate Numbers of
ILC2 Precursors
To determine if miR-155 affected the expansion of ILC2
precursors, we studied the levels of common lymphoid
progenitors (CLP), common helper innate lymphoid progenitors
(CHILP) and ILC2 in the BM of IL-33-treated chimeric mice.
There were no significant differences in BM CLP (Figures 3B,C),
CHILP (Figure 3D), or ILC2 (Figure 3E) Thus, deficits in
progenitor and precursor populations do not underlie the
reduction in ILC2 numbers observed in the lymph nodes
following IL-33 treatment.
miR-155 Increases ILC2 Numbers Through
an ILC2 Intrinsic Mechanism
To establish whether the effect of miR-155 was intrinsic
to ILC2 themselves, and not the actions of miR-155 in
other haematopoetic cells (such as T cells) or indeed miR-
155 containing exosomes derived from other haematopoetic
cells (29, 30), we generated mixed WT/ILC2-deficient or
miR155−/−/ILC2-deficient BM chimeric mice. ILC2-deficient
BM was obtained from Roraflox/flox x Il7raCre mice (1). In
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FIGURE 1 | Differential regulation of miRNAs in ILC2 following activation. (A) PCA analysis of microRNA expression by ILC2 from mice stimulated with IL-33 or
infected with N. brasiliensis (5 d.p.i,). Tetrahedrons represent T cells, spheres represent ILC2, red for IL-33 stimulation, blue for N. brasiliensis exposure and green for
naïve cells. Ellipsoid and colored lines show the relationship between stimulation type and miRNA variation. (B) Relative expression and hierarchical clustering of
miRNA known to be involved with leukocyte activity, relative expression is indicated (red, higher; green, lower). (C) Venn diagram of miRNAs that exhibit a >2-fold
change in expression in IL33 or N. brasiliensis stimulated ILC2 compared with naïve ILC2 and similarly for T cells exposed to N. brasiliensis compared with naive T
cells. Lists of miRNA with the top 5 greatest fold-change values, both upregulated and downregulated, are shown for the indicated sections where applicable. The list
corresponding to the 34 miRNA changed in all 3 populations show the top 5 upregulated and downregulated miRNA in IL33 stimulated compared with naïve ILC2s
are shown. (D) MiR155 log2 transformed data are shown for each sample.
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these mice, the essential ILC2 transcription factor RORα is
deleted in cells expressing the IL-7 receptor. This results in a
depletion of ILC2, while there are no reported defects in T
helper cell function (1, 31). Lethally irradiated WT CD45.1+
(B6SJL) recipient mice received either mixed equal proportions
of WT/ILC2-deficient, or miR155−/−/ILC2 deficient BM. In
these mice, ILC2 are derived from either WT or miR155−/−
cells, but other cells (stromal as well as at least a proportion of
the haematopoetic cells) have unperturbed miR-155 signaling.
While WT ILC2 expanded robustly in response to IL-33, this
expansion was diminished in the absence of ILC2 intrinsic
miR-155 (Figures 4A,B). There were no differences in MLN
T-cell (CD4+–Figure 4C) and B-cells (B220+–Figure 4D) in
the presence or absence of miR-155. These results support an
ILC2-intrinsic role for miR-155 in regulating ILC2 expansion in
response to IL-33.
miR-155 Is Required for ILC2 Expansion
in vitro
To confirm the effects of miR-155 on the expansion of ILC2 that
we observed in vivo, we harvested ILC2 from the mesenteric
lymph nodes (MLN) of mice treated with IL-2/anti-IL-2/IL-
25. Flow cytometrically purified ILC2 were expanded in culture
with IL-7 and IL-33, and cell counts performed at regular
intervals. As suggested by the in vivo data, we observed lower
numbers of ILC2 in the absence of miR-155 (Figure 5A). To
substantiate that this effect was miR-155-specific we transduced
miR-155-deficient ILC2 with a retroviral vector over-expressing
miR-155 (rescue) or a negative control sequence. Retroviral
transduction of miR-155-deficient ILC2 with the negative control
miRNA failed to restore ILC2 number to that of control cultures
(Figure 5A). By contrast, following retroviral transduction with
a vector over-expressing miR-155, miR155−/− cells numbers
were restored to the level of WT ILC2 (Figure 5A). These
findings indicate that the effect of miR-155 in enhancing
ILC2 numbers in vivo is replicated in vitro and specific
to miR-155.
miR-155 Does Not Affect ILC2 Cytokine
Expression
A previous publication reported effects of miR-155 on cytokine
production by ILC2 (20). Hence, we examined whether miR-
155 regulated IL-13 production by ILC2. After 5 days of culture
with IL-7 and IL-33, there were no differences in the percentage
of cells staining positive for intracellular IL-13 in the presence
or absence of miR-155 (Figure 5B). In addition, we quantified
the levels of IL-13 in supernatants collected from cultured
WT and miR155−/− ILC2 (Figure 5C), and ILC2 transduced
with miR-155 knock-down vector (or negative control) using
ELISA (Figure 5D). No differences in the levels of IL-13 were
detected in the supernatants. We also quantified intracellular
IL-13 expression by ex vivo ILC2 obtained from WT/ILC2-
deficient, or miR155−/−/ILC2-deficient chimeric mice treated
intra-peritoneally with IL-33. No differences were found in the
expression of IL-13 in the presence or absence of miR-155
FIGURE 2 | miR-155 is required for ILC2 expansion in response to IL-25 and
IL-33. WT and miR155−/− mice were treated with intra-peritoneal (i.p.) IL-33
(A–C) or IL-2/anti-IL-2/IL-25 complex (D), for 3 days. (A) Representative
staining of ILC2 (CD45+Lin− ICOS+KLRG1+) isolated from mesenteric lymph
node (MLN). (B) Quantification of ILC2 in MLN. (C) Percentage ST2+ WT and
miR155−/− ILC2. (D) Quantification of ILC2 following IL-2/anti-IL-2/IL-25
(IL-25/IL-2C) complex treatment. Data (A,B,D) are representative of three
independent experiments; (C) a single experiment. *p ≤ 0.05 with Student’s
t-test.
(Figure 5E). Taken together these results suggest that miR-155
does not directly regulate IL-13 production by ILC2.
miR-155 Protects Activated ILC2 From
Apoptosis
To further study the mechanism by which miR-155 increases
numbers of ILC2, we assessed potential differences in
proliferation between WT and miR155−/− ILC2. We enriched
ILC2 by negative selection from lymph nodes of IL-33-stimulated
mice, and after 1 week in culture with IL-7 and IL-33, ILC2
proliferation was assessed using Ki67 staining. We detected no
differences in the proportion of Ki67+ ILC2 harvested from WT
andmiR155−/− mice and cultured in vitro (Figures 6A,B).
Since we were unable to obtain evidence for a role
for miR-155 in supporting ILC2 proliferation, we assessed
whether the observed reduction in miR155−/− ILC2 numbers
compared to WT might be explained by increased ILC2 cell
death in the absence of miR-155. WT and miR155−/− ILC2
were expanded in IL-7 and IL-33. Cells were then either
kept in growth medium, or apoptosis was induced using
serum starvation for 6 h. We stained ILC2 using Annexin
V (to detect externalization of membrane phosphatidylserine
as a facet of apoptosis) and viability staining. Even under
normal ILC2 culture conditions the absence of miR-155
resulted in more apoptotic cells in the miR155−/− ILC2
cultures (Figures 6C,D). Furthermore, serum starvation for 6 h
potentiated these differences (Figures 6C,D).
To confirm these findings, we assessed mitochondrial outer
membrane potential (as measured by JC-1 staining), as an
alternative indicator of apoptosis. While there was a trend
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FIGURE 3 | Haematopoetic cell miR-155 is critical for ILC2 expansion. Lethally irradiated B6SJL mice were reconstituted with WT, miR155−/− or mixed
WT/miR155−/− BM, and treated with IL-33 for 3 days. (A) Numbers of ILC2 (live CD45+Lin-CD127+Sca1+KLRG1+ ICOS+) from MLN. (B) Representative staining
of BM progenitor cell populations. (C) Enumeration of BM-derived common lymphoid precursors (CLP: Lin−CD127+Flt3+), (D) common helper innate lymphoid
precursors (CHILP: Lin−CD127+Flt3-a4b7+CD25−), and (E) ILC2 precursors (Lin−CD127+CD25+ST2+). Data are representative of two independent experiments,
n = 4–7. *p ≤ 0.05 with Student’s t-test.
FIGURE 4 | ILC2 intrinsic miR-155 is critical for ILC2 expansion. B6SJL mice were lethally irradiated and received BM from Roraflox/flox x Il7raCre mice alone or in
equal proportions with WT or miR155−/− BM. After 3 months to allow reconstitution, mice were treated with i.p. IL-33 (1 ug/dose) for 3 days. (A) Representative flow
cytometry gating for the indicated populations. (B) Frequency of ILC2 (Lin−CD127+KLRG1+Sca1+) from MLN. Numbers of CD4+ T cells (C) and B cells (D) from
MLN. Data are representative of three independent experiments. *p ≤ 0.05 with ANOVA with Tukey correction.
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FIGURE 5 | miR-155 is required for ILC2 expansion in vitro but not IL-13 production. ILC2 were isolated from MLN of IL-2/anti-IL-2/IL-25 treated WT or miR155−/−
mice. ILC2 were either left untransduced or transduced with a retrovirus over-expressing the miR-155 sequence to restore miR-155 signaling. Cells were cultured for 6
days in the presence of IL-7 and IL-33 (both at 10 ng/ml). (A) Daily ILC2 counts. (B) Intracellular IL-13 staining of WT or miR155−/− ILC2 from 5-day cultures in (A)
analyzed by flow cytometry. (C) Secreted IL-13 was quantified in supernatants from the cultures of WT and miR155−/− ILC2 using ELISA (data corrected for cell
counts). (D) Secreted IL-13 was quantified in supernatants from WT ILC2 treated with negative control siRNA or miR-155 knockdown siRNA harvested after 2 days
using ELISA (data corrected for cell counts). (E) Intracellular IL-13 expression in ILC2 isolated from the MLN of IL-33-treated lethally-irradiated B6SJL mice that had
received mixed BM from Roraflox/flox x Il7raCre mice with WT or miR155−/− BM. Cells were treated with PMA/ionomycin in the presence of protein transport inhibitor.
Data are representative of at least two independent experiments. Two-way ANOVA with Sidak’s multiple comparisons test (A), #p ≤ 0.05 compared to miR155−/−,
§p ≤ 0.05 compared to control transduced miR-155−/− ILC2.
toward an increase in apoptosis in miR155−/− ILC2 cultures in
complete medium as compared to WT controls (Figures 6E,F),
this increase in apoptosis reached statistical significance after
6 h of serum starvation (Figures 6E,F). Although we also
investigated the presence of markers of apoptosis directly ex vivo,
we found there were very few apoptotic ILC2 in the LN of
IL-33-treated mice, likely because apoptotic cells are rapidly
cleared in the tissue. Together, our data indicate that the
expression of miR-155 protects ILC2 from apoptosis during
activation.
DISCUSSION
ILC2 are key players in type-2 immunity, and an understanding
of their regulation and biology offers an opportunity for
the development of new therapeutic targets in type-2
immune-mediated diseases such as asthma and allergy. Using
comprehensive miRNA microarray and RT-qPCR strategies we
identified a group of miRNAs whose expression was regulated
in response to ILC2 activation in vivo, following either IL-33
treatment orN. brasiliensis infection, compared to naïve controls.
Additional miRNAs were also regulated uniquely in response
to IL-33 administration or worm infection, respectively. Of the
shared miRNAs several have been associated with the regulation
of cell growth and proliferation e.g. miR-93 (32, 33), miR-25
(34), miR-103 (35). Notably, others are known to regulate
immune function, including miR-155, mir-146a and let-7a and
let-7d (36). Furthermore, our data show good concordance with
the ILC2 miRNA expression reported recently by Singh et al.
using small RNA-sequencing (17). They went on to show that
ILC2 deficient in the miR-17∼92 cluster were less proliferative
than wildtype controls, though the rate of apoptosis was not
affected. miRNA-19a, located in the miR-17∼92 cluster was also
required for optimal IL-5 and IL-13 production by ILC2, and
this contributed to allergic inflammation (17).
It has been reported recently that both miR-155 and miR-
146a are required for the type-2 response to helminth infection.
MiR-146a-deficient mice are unable to clear Trichuris muris
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FIGURE 6 | miR-155 protects ILC2 from undergoing apoptosis. LNs were excised from IL-33-treated WT and miR155−/− mice and CD3+, B220+, CD11b+, and
CD11c+ cells depleted using dynabeads. The remaining cells were cultured in 10 ng/ml IL-7 and IL-33 for 1 week and ILC2 proliferation assessed using Ki67 staining.
(A) Representative flow cytometry for Ki67 staining. (B) Proportion of Ki67-positive ILC2 from LN analyzed ex vivo from WT and miR155−/− mice treated in vivo with
IL-33 for 3 days. (C,D) Annexin V and viability staining of ILC2. WT or miR155−/− ILC2 were isolated from MLN of IL-2/anti-IL-2/IL-25- or IL-33- treated animals and
then expanded in vitro in the presence of IL-33 for 5 days. Following culture, cells were either kept in growth medium or serum-starved (in RPMI only) for 6 h.
(C) Representative FACS plots. (D) Enumeration of live vs. apoptotic cells. (E,F) Mitochondrial depolarisation was assessed using JC-1 staining (culture as for C,D).
(E) Representative FACS plots. (F) Enumeration of live vs. apoptotic cells. Data are representative of two (B–D) or three (E,F) independent experiments. Student’s
t-test, *p ≤ 0.05.
infection, associated with a decrease in IL-13-producing T cells
and an increase in IL-17-secreting T cells (19). Heligmosomoides
polygyrus infection of miR-146a-deficient mice led to a decrease
in the proportion of IL-5-producing T cells with an increase
in IL-17 and IFN-γ producing T cells, suggesting that miR-
146a was responsible for polarizing T cells to a Th2 profile.
Furthermore, miR-155-deficient mice were also unable to mount
a Th2 response when infected with H. polygyrus and miR-155
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was upregulated in Th2 cells as well as the cells around the
intestinal lesions during an H. polygyrus infection (19). MiR-
155-deficient mice also had significantly lower IL-13 expression
and airway mucus in response to house dust mite challenge
(19), and impaired responses to an OVA-model of allergic
airway inflammation (18). Additionally, miR-155 has been
shown to play key roles in other cell types and immune
responses. In the absence of miR-155, mice fail to produce
high affinity IgG1 and have smaller germinal centers (37–
39). MiR-155 is also crucial in Th17 cells (40), and mice
deficient in miR-155 are resistant to experimental autoimmune
encephalitis due to reduced production of Th17 and Th1
responses (41). Furthermore, in the absence of miR-155, CD8
T-cell responses against viruses and tumors are impaired (42).
Finally, a recent report showed that ILC2 proliferate less
readily in the absence of miR-155, however, an ILC2-intrinsic
requirement for miR-155 in vivo was not explored and the
mechanism by which miR-155 increased ILC2 numbers was not
determined (20).
We confirmed that there are fewer ILC2 in the lymph
nodes of IL-33-treated miR-155-deficient mice compared to
WT controls, and that this is due to an ILC2-intrinsic role
for miR-155 in maintaining ILC2 numbers during immune
activation by protecting them from apoptosis. While miR-
155 is widely expressed in haematopoetic cells, several reports
indicate expression in stromal tissues, including epithelial cells.
Generating BM chimeric mice allowed us to demonstrate
that the effects of miR-155 on ILC2 were dependent on the
haematopoetic compartment. Furthermore, by generating mixed
BM chimeras using miR155-deficient BM and ILC2-deficient BM
from Roraflox/flox x Il7raCre mice, we established that the effect of
miR-155 on ILC2 numbers is intrinsic to ILC2. This effect was
recapitulated in vitro, with fewer miR155−/− ILC2 present after
culture with IL-7 and IL-33 as compared to WT ILC2, and this
was rescued by retroviral over-expression of miR155.
Interestingly, there were no differences in BM ILC2
precursors, such as haematopoetic stem cells, CLP or CHILP
in the presence or absence of miR-155. Thus, miR-155 did
not appear to regulate ILC2 numbers in vivo by increasing
proliferation of ILC2 precursors. Also, there were no differences
in BM ILC2. Hence, it is unlikely that the increased numbers of
ILC2 in peritoneal lymph nodes were caused by increased ILC2
progenitor production.
Notably, although others have reported a defect in miR-155-
deficient ILC2 proliferation (20), we did not observe differences
in the presence of Ki67+ ILC2 cultured in vitro or when
analyzed ex vivo, as compared to WT controls. In contrast to
Johansson et al. who assessed the percentage of total Ki67+Lin−
cells compared to total lung cells (which does not take into
account the differences in ILC2 numbers that are present in the
absence of miR-155), we specifically determined the proportion
of proliferating ILC2 compared to total ILC2 to account for
the differences in total ILC2 numbers in the miR155−/− mice.
Furthermore, as others have also reported effects of miR-155
on cytokine production (21), and indeed on the production of
IL-13 by ILC2 (20), we measured IL-13 production by ILC2 in
the presence or absence of miR-155. However, we did not find
any differences in the ability of ILC2 to produce IL-13 in the
presence or absence of miR-155, as measured by ELISA and
intracellular cytokine staining. It is not clear why these data
differ, though the mouse lines used in the different studies, or
the facilities, could contribute. Our study employed the mir-
155-deficient mouse strain (Mir155tm1.1Brd) generated by Bradley
and colleagues (21), whilst Johanssen et al. used the miR155−/−
mice (Mir155tm1.1Rsky) from Rajewsky and colleagues (38). Both
groups targeted exon 2 in 129Sv-derived embryonic stem cells,
removed the neomycin selection cassette, and backcrossed to
a C57BL/6 background. However, the Mir155tm1.1Rsky line also
retains a LacZ reporter. An alternative explanation for the
differences observed is that our study and that of Johannson et al.
investigated ILC2 from different tissues; lymph nodes or lungs,
respectively. Consequently, variances may arise from the kinetics
of the response and the time-points analyzed.
Since we had confirmed that the effects of miR-155 on
ILC2 numbers were preserved in response to IL-25, and that
miR-155 did not alter ST2 levels, it is unlikely that miR-155
interferes with IL-33 receptor signaling specifically. However,
using two different methods to quantify apoptosis (JC-1 staining
as a measure of loss of mitochondrial membrane potential,
and annexin V), we identified that miR-155 expression protects
stressed ILC2 from undergoing apoptosis, thereby maintaining
and increasing ILC2 numbers. Previous studies have linked miR-
155 to apoptosis, both in pro- and anti-apoptotic roles. MiR-
155 has also been shown to be pro-apoptotic in acute myeloid
leukemia (43) and human dendritic cells (44). However, extensive
evidence links miR-155 with anti-apoptotic functions, including
in immune cells. In pancreatic cancer ductal cells, miR-155
targets tumor protein 53-induced nuclear protein 1, resulting
in decreased apoptosis and increased tumorogenic potential
(45). Others have suggested that miR-155 targets caspase-3
and Fas-associated protein with death domain (FADD) directly
to protect cells from apoptosis (46). In psoriasis, miR-155 is
thought to result in increased proliferation and reduced apoptosis
by targeting the PTEN signaling pathway (47). FOXO3 is a
target of miR-155, and miR-155 inhibits apoptosis by targeting
FOXO3 in monocytes (48) and T cells (49). In B cells, JARID2
is targeted by miR-155, inhibiting apoptosis and resulting in
germinal center B cell expansion through collaboration with
c-Myc (50). To our knowledge our data are the first linking
miR-155 to the control of apoptosis in innate lymphoid cells.
Interestingly, recent studies have also indicated that miR-155
promotes autophagy to protect cells during stresses such as
hypoxia and nutrient deprivation (51, 52). Thus, it is possible
that in the absence of miR-155 ILC2 have impaired autophagy
and that this contributes to their decreased survival. However,
further studies will be required to identify miR155 target genes
in the regulation of apoptosis in ILC2, and to investigate
potential links between miR155 and autophagy-associated cell
death (53).
In summary, we present a comprehensive analysis of miRNA
changes in ILC2 in response to activation and demonstrate that
miR-155 increases ILC2 frequency in response to stimulation
by reducing apoptosis. Although we were unable to identify the
target(s) of miR-155 that orchestrate control of apoptosis in ILC2,
our data provide a novel pathway for the regulation of ILC2
through apoptosis.
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